Evidence map›Paper›PMID 34599863›Full record

ArticleCancer medicine2021

Driver gene alterations profiling of Chinese non-small cell lung cancer and the effects of co-occurring alterations on immunotherapy.

Shengjie Sun, Wenjuan Du, Qiong Sun, Xiao Zhao, Boyu Qin, Duozhi Shi, Chong Wan, Zhiyong Wu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Shengjie SunMedical Oncology Department, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
Wenjuan DuTraining Department of Medical Service Department, General Hospital of People's Liberation Army, Beijing, China.
Qiong SunMedical Oncology Department, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
Xiao ZhaoMedical Oncology Department, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
Boyu QinMedical Oncology Department, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
Duozhi ShiDepartment of Medicine, Lifehealthcare Clinical Laboratories, Hangzhou, China.ORCID 0000-0002-3290-3461
Chong WanDepartment of Medicine, Lifehealthcare Clinical Laboratories, Hangzhou, China.
Zhiyong WuMedical Oncology Department, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
Chinese PLA General Hospital · CNMemorialCare Health System · USPeople's Liberation Army No. 150 Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMolecular testing for alterations in oncogenic driver genes and targeted therapies have become standard procedures for non-small cell lung cancer (NSCLC) patients. However, little evidence has shed light on the pattern of co-existence of driver genes in NSCLC, and whether they may have different tumor features affecting immunotherapy is still unclarified.

methodsGenomic alterations in 14 lung cancer-related genes were conducted in 3440 Chinese NSCLC patients using next-generation sequencing. Meanwhile, tumor mutational burden and immunotherapy dataset from the Memorial sloan kettering cancer center (MSKCC) and lung adenocarcinoma dataset from The Cancer Genome Atlas (TCGA) were utilized for analyzing the impact of the co-occurring alterations on patients' survival following immunotherapy.

resultsIn this cohort, 90.17% of patients had at least one somatic alteration in the 14 genes, including 51% of co-occurring alterations. TP53 and epidermal growth factor receptor (EGFR) were the most prevalent genes (54.74% and 53.55%, respectively), followed by KRAS, ERBB2, ALK, PIK3CA, ROS1, RET, MET, BRAF, KIT, FGFR1, PDGFRA, and NRAS. The prevalence of TP53, EGFR, and ERBB2 in our cohort were significantly higher than that from the TCGA database, whereas KRAS, BRAF, and PDGFRA were significantly lower than the latter. Furthermore, the patients who harbored multiple alterations (8.86%, 31/350) in eight driver genes survived longer and have a higher tumor mutation burden compared to the patients with a single alteration. Similar result was found between the patients with co-occurring alteration of EGFR and other driver genes and the patients with single EGFR alteration. Meanwhile, we found a distinct immune cell infiltration feature between patients with single and multiple driver gene alterations, as well as between patients with only EGFR alteration and co-occurring groups.

conclusionThis study identified a unique driver gene feature and found patients harboring co-occurring alterations of EGFR and other driver genes may benefit from immunotherapy, which may provide more therapeutic selections for EGFR-mutated NSCLC patients and merit additional investigation.

Indexed as

AdultAgedAged, 80 and overAsian PeopleCarcinoma, Non-Small-Cell LungCohort StudiesFemaleGenetic ProfileGenomicsHumansImmunotherapyLung NeoplasmsMaleMiddle AgedProgression-Free SurvivalYoung Adultco-occurringdriver genesEGFRimmunotherapynon-small cell lung cancersomatic alterations

Identifiers

PMID34599863
PMCPMC8525092
OpenAlexW3201891297

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.